Why the study?
Do PCC, aPCC, rFVIIa, or a specific antidote (aDabi-Fab) reverse the anticoagulant effects of dabigatran ex-vivo in a porcine trauma model?
Population
Porcine model of trauma treated with dabigatran etexilate to achieve supratherapeutic concentrations
Comparison
Ex-vivo addition of prothrombin complex… vs Blood samples without ex-vivo reversal agents
Design
Preclinical
Authors
Loading...
Supports specific dabigatran antidote development; hypothesis-generating in porcine model, requires human validation before practice change.
Do PCC, aPCC, rFVIIa, or a specific antidote (aDabi-Fab) reverse the anticoagulant effects of dabigatran ex-vivo in a porcine trauma model?
In a preclinical porcine trauma model, a specific dabigatran antidote fully reversed dabigatran-induced anticoagulation, whereas PCC and aPCC provided partial reversal and rFVIIa was ineffective.
Grottke et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: